Abstract
Purpose :
The objective of this study was to review the cases of neurotrophic keratopathy with use of a new ReGeneraTing Agent (RGTA) Cacicol®.
Methods :
An analysis was based on documents retrieved from the literature search. The case reports, in which Cacicol® poly(carboxymethyl glucose sulfate) had been used in the management of neurotrophic keratopathy and which were refractory to conventional therapies were eligible. Bibliometric analysis was performed using own designed database. In all groups posology, duration of treatment, healing level and tolerance have been assessed by descriptive methods.
Results :
Through the literature search, 37 eligible reports have been qualified for the review: 241 eyes of 234 patients were investigated and grouped based on described etiology: neurological (n=32), post-infectious (n=30), postoperative (n=23), chemical burns (n=12), isolated cases (n=34) and unspecified history (n=110). Analysis revealed that more than 76% of eyes achieved complete corneal healing regardless of the etiology group. In the most cases, posology covered 1 drop every other day. The overall complete response rate increased with time of prolonged RGTA use: almost 60% and 84% of eyes (N=75) completely healed after 1 and 2 months, respectively. Recurrent neurotrophic ulcers after the complete healing were reported in 10 of 73 investigated eyes with available information. Two cases with safety concerns were observed, but with no causality assessment of RGTA.
Conclusions :
Use of the new matrix therapy agent Cacicol® facilitates corneal healing. It might be considered as an alternative approach in the neurotrophic keratopathy management. However randomized clinical trials are necessary to confirm the promising effect.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.